The Journal of urology
-
The Journal of urology · Jan 2001
Comparative StudyMedical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.
We provide a relative cost comparison of medical versus surgical androgen suppressive therapy for prostate cancer. ⋯ Except for patients with short anticipated survivals current medical androgen suppressive treatment options are more costly than bilateral orchiectomy. There is a need for a cost comparable medical option to orchiectomy.
-
The Journal of urology · Jan 2001
Clinical TrialThe use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
Hormone refractory prostate cancer is dominated by osseous metastases leading to bone pain and pathological fractures. We assessed the clinical efficacy of bisphosphonate in the management of symptomatic skeletal metastases due to prostate cancer. ⋯ Bisphosphonate treatment of painful osseous metastases due to hormone refractory prostate cancer results in a significant pain decrease and a significant decrease in the daily consumption of analgesics in 75% of patients. Each characteristic is paralleled by an increase in the Karnofsky index, mainly due to better mobility. Bisphosphonate should have a definite role in the palliative management of symptomatic hormone refractory prostate cancer.